发布求助
文献互助 智能选刊 最新文献

Seminarios de la Fundación Espa?ola de Reumatología最新文献

筛选
英文 中文
Evidencias sobre la eficacia de los tratamientos biológicos en las vasculitis sistémicas 关于生物治疗系统性血管炎有效性的证据
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-07-01 Epub Date: 2011-08-04 DOI: 10.1016/j.semreu.2010.05.005
María Granados Ruiz, Inmaculada Gómez Gracia, M. Ángeles Aguirre Zamorano
{"title":"Evidencias sobre la eficacia de los tratamientos biológicos en las vasculitis sistémicas","authors":"María Granados Ruiz,&nbsp;Inmaculada Gómez Gracia,&nbsp;M. Ángeles Aguirre Zamorano","doi":"10.1016/j.semreu.2010.05.005","DOIUrl":"https://doi.org/10.1016/j.semreu.2010.05.005","url":null,"abstract":"<div><p>In recent decades, there has been a breakthrough in the treatment of systemic vasculitis, although substantial morbidity and mortality are still associated with these diseases, often related to immunosuppressive therapy. The success of biologic therapy in rheumatoid arthritis and other autoimmune diseases has led to research into these agents in systemic vasculitis. Anti-tumor necrosis factor (TNF) agents have proven useful in the treatment of Takayasu arteritis refractory to conventional treatment but there is no evidence of their effectiveness in other types of vasculitis. Anti-CD20 therapy (rituximab) has proven effective in ANCA vasculitis refractory to cyclophosphamide. Two recently published clinical trials have shown that rituximab is not inferior to cyclophosphamide as induction therapy of remission in ANCA Vasculitis, so in the future, could be considered a first line treatment in these patients.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 3","pages":"Pages 73-78"},"PeriodicalIF":0.0,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.05.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72279119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2011.04.001
Francisco Javier, López Longo
{"title":"","authors":"Francisco Javier,&nbsp;López Longo","doi":"10.1016/j.semreu.2011.04.001","DOIUrl":"https://doi.org/10.1016/j.semreu.2011.04.001","url":null,"abstract":"","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 62-64"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91719695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ABC de la insuficiencia cardiaca 心脏衰竭的ABC
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2010.05.004
Agustín Urrutia de Diego , Javier Santesmases Ejarque , Josep Lupón Rosés
{"title":"ABC de la insuficiencia cardiaca","authors":"Agustín Urrutia de Diego ,&nbsp;Javier Santesmases Ejarque ,&nbsp;Josep Lupón Rosés","doi":"10.1016/j.semreu.2010.05.004","DOIUrl":"10.1016/j.semreu.2010.05.004","url":null,"abstract":"<div><p>Heart failure (HF) is a highly prevalent syndrome. In Spain the prevalence is 7-8%, representing a substantial healthcare burden and one of the most frequent diagnoses in internal medicine. The major causes of HF are hypertensive heart disease, dilated cardiomyopathy and high blood pressure. These causes vary in importance depending on the population studied. Because the signs and symptoms of HF are non-specific, clinical diagnosis is not easy. Several clinical diagnostic criteria are available for better standardization, the most widely used being the Framingham criteria. All patients with HF should undergo echocardiography. Determination of B-type natriuretic peptide (BNP) (or pro-BNP) is an important diagnostic aid. Mortality is high, between 40% and 50% at 5 years. The availability of angiotensin converting-enzyme inhibitors and beta blockers (to be used in all patients without contraindications) has represented a huge advance in the treatment of this syndrome. However, many of these patients will be treated in the final stage of their disease and will require a more palliative than curative approach.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 42-49"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.05.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127125996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Fe de errores de “La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab” “RANKL抑制治疗骨质疏松症:denosumab”错误Fe
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2011.04.002
Luis Pérez Edo
{"title":"Fe de errores de “La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab”","authors":"Luis Pérez Edo","doi":"10.1016/j.semreu.2011.04.002","DOIUrl":"10.1016/j.semreu.2011.04.002","url":null,"abstract":"","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Page 61"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"96932577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab 白介素-6受体抑制剂治疗类风湿关节炎的安全性和剂量
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2011.02.003
Melania Martínez-Morillo, Dolors Grados, Beatriz Tejera, Alejandro Olivé Marqués
{"title":"Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab","authors":"Melania Martínez-Morillo,&nbsp;Dolors Grados,&nbsp;Beatriz Tejera,&nbsp;Alejandro Olivé Marqués","doi":"10.1016/j.semreu.2011.02.003","DOIUrl":"10.1016/j.semreu.2011.02.003","url":null,"abstract":"<div><p>Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 57-60"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113939071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Terapia biológica en el lupus eritematoso sistémico. ¿Hay vida más allá del linfocito B? 系统性红斑狼疮的生物治疗。B淋巴细胞之外还有生命吗?
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2010.08.001
Teresa Otón, Mónica Fernández Castro, Lucía Silva Fernández, José Luis Andreu
{"title":"Terapia biológica en el lupus eritematoso sistémico. ¿Hay vida más allá del linfocito B?","authors":"Teresa Otón,&nbsp;Mónica Fernández Castro,&nbsp;Lucía Silva Fernández,&nbsp;José Luis Andreu","doi":"10.1016/j.semreu.2010.08.001","DOIUrl":"10.1016/j.semreu.2010.08.001","url":null,"abstract":"<div><p>Current treatment options for systemic lupus erythematosus (SLE) fail to control all the manifestations of the disease or fully prevent flares. The most extensively studied biological therapies are directed against B cells, although other biological targets have also been explored. Biological agents against tumor necrosis factor-alfa differ in their efficacy and have been associated with the generation of antinuclear and anti-dsDNA antibodies. Anti-interleukin-10 and anti-interleukin-6 agents have also been studied, with encouraging results. Abatacept, which has been approved in rheumatoid arthritis, has not shown efficacy in placebo-controlled clinical trials.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 50-52"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55152687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
¿Conoces a Atul? “concones a Atul?”
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2011.02.001
Alejandro Olivé
{"title":"¿Conoces a Atul?","authors":"Alejandro Olivé","doi":"10.1016/j.semreu.2011.02.001","DOIUrl":"10.1016/j.semreu.2011.02.001","url":null,"abstract":"","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Page 35"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125270255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artropatía de Jaccoud: algo más que lupus 雅库德关节病:不仅仅是狼疮
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2010.10.001
Francisco Javier López Longo
{"title":"Artropatía de Jaccoud: algo más que lupus","authors":"Francisco Javier López Longo","doi":"10.1016/j.semreu.2010.10.001","DOIUrl":"10.1016/j.semreu.2010.10.001","url":null,"abstract":"<div><p>Jaccoud's arthropathy (JA) occurs in 5% of patients with systemic lupus erythematosus and causes deformities in the hands and feet due to intermittent inflammation of the periarticular soft tissues, including tendons and joint capsules. These deformities include subluxation of the metacarpophalangeal joints, ulnar deviation of the 2nd to 5th fingers, swan neck deformities, Z deformity of the thumb, hallux valgus, subluxation of the metatarsophalangeal joints and other, non-erosive subluxations. In the early stages of the disease, these deformities are reversible but become irreversible in the long-term and usually require surgical correction. The clinical management of JA is always aimed at early control of joint inflammation and preventing severe limitation of movement and persistent loss of joint function.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 36-41"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132934671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Vasculopatía livedoide 类活化血管病
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-04-01 Epub Date: 2011-05-10 DOI: 10.1016/j.semreu.2010.11.001
María del Carmen Fernández-Antón Martínez
{"title":"Vasculopatía livedoide","authors":"María del Carmen Fernández-Antón Martínez","doi":"10.1016/j.semreu.2010.11.001","DOIUrl":"https://doi.org/10.1016/j.semreu.2010.11.001","url":null,"abstract":"<div><p>Livedoid vasculopathy is a rare disease characterized by chronic, painful ulceration of the lower limbs that tends to progress to white atrophic lesions (atrophie blanche). These lesions are not pathognomonic but are the result of multiple processes. Livedoid vasculopathy is much more common in females, and usually occurs bilaterally in the distal third of the lower extremities.</p><p>Diagnosis is not easy and is often not made until the disease has progressed. Consequently clinical and pathological correlation is required to suspect this entity. Biopsy of skin lesions aids diagnosis, but lacks pathognomonic findings. A broad therapeutic arsenal is available, which should be assessed individually according to the characteristics of each patient.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 53-56"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137283524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab 抑制RANKL在骨质疏松治疗中的作用:denosumab
Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 Epub Date: 2011-03-16 DOI: 10.1016/j.semreu.2010.11.003
Luis Pérez Edo
{"title":"La inhibición del RANKL en el tratamiento de la osteoporosis: denosumab","authors":"Luis Pérez Edo","doi":"10.1016/j.semreu.2010.11.003","DOIUrl":"10.1016/j.semreu.2010.11.003","url":null,"abstract":"<div><p>Denosumab is a human monoclonal antibody IgG2 against RANKL that prevents the coupling of the RANKL with its receptor RANK on osteoclast and osteoclast precursors, which is essential for the formation, activity and survival of osteoclasts, disabling the bone resorption. The action of the Denosumab on bone remodeling is rapid, sustained and reversible. The recommended dose is of 60<!--> <!-->mg for subcutaneous route every 6 months. The reduction of the relative risk of new vertebral fractures is of 68% (2.3% vs 7.2%, p<!--> <!-->&lt;<!--> <!-->0.0001), 20% (6.5% vs 8.0%) in non vertebral fractures and 40% (0.7% vs 1.2%) in the case of the of hip. At 36 months the lumbar bone mineral density increased 9.2% and 6.2% in the total hip, in comparison with the placebo. It is a safe drug with a low incident of cutaneous effects. The frequency and route of administration can be useful to improve the compliance of the osteoporosis treatment.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 1","pages":"Pages 27-30"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133196043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书